Managing Brain Metastases in ALK+ NSCLC

In the September 2025 issue of Medicina Scientia, Shalata et al. published a systematic review evaluating the efficacy of tyrosine kinase inhibitors (TKIs) in ALK- and EGFR-mutated non-small cell lung cancer (NSCLC) with brain metastases. While the review evaluates both EGFR- and ALK-mutated NSCLC, we’re going to focus on ALK-rearranged disease.

ALK gene rearrangements occur in approximately 4.5% of NSCLC patients, mainly in adenocarcinoma. CNS involvement is frequent: about 20% of ALK-positive patients present with brain metastases at diagnosis, and 40 to 50% develop CNS metastases during their disease course. The authors emphasize that ALK rearrangements appear to confer a biologic advantage for CNS colonization, making early intracranial surveillance and CNS-penetrant therapy essential.

A defining challenge shaping the treatment landscape in ALK-rearranged NSCLC has been the blood-brain barrier (BBB). Restricted drug permeability and active efflux transporters, such as P-glycoprotein, historically limited CNS drug concentrations.

Shalata et al. conducted a systematic PubMed search through July 2025, including studies of NSCLC patients with brain metastases treated with TKIs and reporting intracranial response rates, progression-free survival (PFS), overall survival (OS), and safety outcomes.

Evolution of ALK-Targeted TKIs and Intracranial Efficacy
The first-generation ALK inhibitor crizotinib improved systemic control but demonstrated limited BBB penetration. CNS progression frequently represented the primary site of relapse, with modest intracranial response rates and limited median PFS in patients with baseline brain metastases.

Second-generation ALK inhibitors were engineered to enhance BBB penetration and overcome resistance. Alectinib showed clear superiority over crizotinib, achieving intracranial objective response rates (IC-ORR) of 78.6% in patients without prior radiotherapy and 85.7% in previously irradiated patients. Intracranial median PFS reached 36 months. Brigatinib similarly achieved IC-ORR rates above 75% and intracranial PFS approximately 24 months in treatment-naïve patients.

Third-generation therapy now represents the benchmark. Lorlatinib, designed to optimize CNS penetration and maintain activity against resistance mutations, demonstrated striking results in the phase III CROWN trial. The IC-ORR was 60%, with approximately 49% of patients achieving complete intracranial responses. Median intracranial progression was not reached in the first-line setting, and 92% of patients remained free of CNS progression at five years. Lorlatinib also showed a strong preventive effect against the development of new brain metastases.

Across generations, improved BBB penetration consistently correlated with higher intracranial response rates and prolonged PFS. These findings support the preferential use of second- and third-generation ALK TKIs in patients with brain metastases or at high risk for CNS involvement.

Combination with Radiotherapy
The integration of ALK TKIs with radiotherapy remains under investigation. Some retrospective studies suggest improved intracranial PFS and OS with combined approaches, while other meta-analyses show no consistent survival advantage over TKI alone. Variability in study design, TKI generation, and radiotherapy modality likely contribute to these differences.

Safety Considerations and Resistance
As CNS efficacy improves, toxicity profiles evolve. Among ALK inhibitors, serious adverse event (SAE) incidence varies: alectinib demonstrates the lowest reported rate (26.24%), compared with ceritinib (41.44%), brigatinib (41.68%), and crizotinib (38.09%).

Lorlatinib introduces a distinct safety profile, including metabolic syndrome (hypercholesterolemia in 72% and hypertriglyceridemia in 66%) and neurocognitive adverse events in approximately 40% of patients, though most are grade 1-2. Enhanced CNS penetration is therefore accompanied by CNS-specific toxicities requiring vigilant monitoring, particularly as patients may remain on therapy long term.

Despite therapeutic advances, resistance remains a challenge. Secondary ALK mutations (e.g., G1202R), bypass signaling activation, tumor heterogeneity, and pharmacokinetic barriers within the CNS microenvironment contribute to eventual disease progression.

Overall, this review underscores significant advancements in the treatment landscape for ALK-rearranged NSCLC with brain metastases. Proactive, personalized strategies, including next-generation ALK TKIs, continue to shape intracranial disease control and influence long-term outcomes.

Reference:
Shalata W, Naamneh R, Najjar W, et al. Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Med Sci (Basel). 2025;13(3):200. Published 2025 Sep 18. doi:10.3390/medsci13030200